SA has 57,471 active cases of Covid-19



South Africa has 57,471 active cases of Covid-19, out of a total of 3,931,534 confirmed cases and 3,773,111 cured.

The country has identified 1,662 new cases of Covid-19 in the past 24 hours. This increase represents a 13.7 percent positivity rate, announced the National Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service.

25 081 137 tests were conducted in both the public and private sectors. Most of the new cases today come from Gauteng (39%) followed by Western Cape (22%). KwaZulu-Natal accounted for 13%; Free State accounted for 6%; Mpumalanga and North West accounted for 5% each respectively; Eastern Cape and Northern Cape accounted for 4% each respectively; and Limpopo accounted for 1% of cases today.

The NICD reported 19 deaths and of these, 8 occurred in the past 24-48 hours. This brings the total casualties to 100,952 to date.

“Due to the ongoing audit exercise by the National Department of Health (NDoH), there may be a backlog of reported Covid-19 mortality cases.”

There has been an increase of 83 hospital admissions in the past 24 hours.

Pfizer Covid-19 vaccine for less than five years effective with three doses

The Pfizer-BioNTech Covid vaccine is safe and effective when given in three doses to children under the age of five, the companies said Monday, good news for parents in the only age group not yet eligible for immunization in most. part of the countries.

The announcement comes as the U.S. Food and Drug Administration (FDA) is planning highly anticipated meetings in the coming weeks to consider the authorization.

In a clinical study, Pfizer-BioNTech evaluated three doses, given at three micrograms, and found that the vaccine evoked a strong immune response in children aged six months to four years.

Side effects were similar in the vaccine and placebo groups.

The efficacy of the vaccine was 80.3 percent, according to a preliminary estimate, although this was based on very low numbers and could change significantly at the time of the final estimate.

“We are delighted that our formulation for younger children, which we carefully selected to be one-tenth the adult dose, was well tolerated and produced a strong immune response,” said Albert Bourla, Pfizer CEO.

“We look forward to completing our requests to regulators globally soon with the hope of making this vaccine available to younger children as quickly as possible, subject to regulatory clearance,” he added.

Further reporting by the AFP